Ribosome-inactivating proteins (RIPs) are a family of enzymes that depurinate rRNA and inhibit protein biosynthesis. Here we report the purification, apoptosisinducing activity, and polyethylene glycol (PEG) modification of RIP from the bitter melon seeds. The protein has a homogenous N-terminal sequence of NAsp-Val-Ser-Phe-Arg. Moreover, the RIP displayed strong apoptosis-inducing activity and suppressed cancer cell growth. This might be attributed to the activation of caspases-3. To make it available for in vivo application, the immunogenicity of RIP was reduced by chemical modification with 20 kDa (mPEG) 2 -Lys-NHS. The inhibition activity of both PEGylated and nonPEGylated RIP against cancer cells was much stronger than against normal cells, and the antigenicity of PEGylated RIP was reduced significantly. Our results suggested that the PEGylated RIP might be potentially developed as anti-cancer drug.
Introduction
Ribosome inactivating proteins (RIPs) from angiosperm species [1 -3] , fungal species [2 -5] , and bacteria [2] are a family of RNA N-glycosidases, which inactivate ribosome through the site-specific deadenylation of the large ribosomal RNA [1, 6] , and the mechanism of cell entry and intracellular trafficking of certain types of RIPs has been well studied [7] . Recent studies demonstrated that RIPs also have anti-tumor and anti-viral properties [8] . For example, MAP30, a 30 kDa single-stranded RIP, was found to be able to inhibit HSV-2 and HSV-1 viral proliferation [9, 10] . Interestingly, MAP30 also showed robust and broad anti-cancer activities against multiple cancer cells such as lymphoid leukemia, lymphoma, choriocarcinoma, melanoma, breast cancer, skin tumor, prostatic cancer, squamous carcinoma, human bladder carcinomas, and Hodgkin's disease [11] [12] [13] [14] [15] . The anti-cancer activities of RIPs are primarily attributed to apoptotic pathway. Based on these features, researchers are attempting to take advantage of the multi-functions of the RIP to develop RIP-based drugs for anti-viral infection and anti-cancers. However, the strong immunogenicity of RIPs has significantly limited their clinical applications.
Different approaches, such as site mutagenesis, protein chemistry and modification, have been employed to reduce the immunogenicity of RIPs. Among them, PEGylation has been found to be very effective [16] . The chemical attachment of polyethylene glycol (PEG) to therapeutic proteins led to several benefits: the extended plasma half-life, lower toxicity, and increased drug stability and solubility [16] . PEGylation also reduced antigenicity of foreign proteins and less likely trigger immune rejection in human. The Food and Drug Administration has approved the PEGylated forms of the therapeutic proteins such as adenosine deaminase, asparaginase, a-IFN, and a growth hormone antagonist [17] .
In this study, we first purified the RIP from bitter melon seeds and then carried out PEG modification. PEGylation of the RIP (RIP-PEG) did not significantly affect its anti-tumor activity as measured by the caspase-3 assay, DNA fragmentation, and morphological analysis. Most importantly, the in vivo immunogenicity analysis indicated that RIP-PEG triggered much weaker immune response as indicated by 70% decrease of antigenspecific serum IgG levels. This work may facilitate future clinical investigations of bitter melon RIP. Purification of RIP from bitter melon seeds Decorticated dried ripe bitter melon seeds were ground and homogenized in cold 50 mM HAC -NaAC buffer, pH 5.0. The slurry formed was stirred for 12 h at 48C and then centrifuged at 15,000 g for 30 min at 48C. After filtering through cheesecloth, the supernatant was fractionated by precipitation with ammonium sulfate (30-60%). The precipitate was dissolved and dialyzed against 50 mM sodium phosphate ( pH 7.0) for 12 h at 48C. The dialyzed sample was passed through a SP-Sepharose FF column equilibrated with the dialysis buffer. The retained protein was eluted with a linear gradient of 0-1 M NaCl in 50 mM sodium phosphate, pH 7.0, at a flow rate of 1 ml/min. The fractions were monitored by UV detector at 280 nm and analyzed by 12% SDS-PAGE. The fractions containing significant 30 kDa were collected and concentrated properly. The concentrated sample was further applied to a Superdex 75 column and eluted with 50 mM sodium phosphate ( pH 7.0) containing 0.15 M NaCl, at a flow rate of 1.5 ml/min. The fractions containing ribosome inactivating protein, analyzed by 12% SDS-PAGE, were pooled, concentrated and then dialyzed against 50 mM sodium phosphate, pH 7.0. After passing through a 0.22-mm filter, the concentrated ribosome inactivating protein was stored at 48C before use. Protein concentration was determined with the method of Lowry et al. [18] , using bovine serum albumin as the standard.
Materials and Methods

Materials
Chemical synthesis of RIP-PEG conjugate Fifty micrograms of PEG powder was added to 2.5 ml of 2 mg/ml RIP in 0.05 M borate buffer ( pH 8.5) and was quickly mixed with gentle stirring at 48C for 30 min. Reactive products were applied to a Superdex 200 column, which was previously equilibrated with 50 mM phosphate buffer ( pH 7.0) containing 0.15 M NaCl, and then column was eluted with the same equilibrium buffer at 1.5 ml/min of flow rate. The fractions were monitored by UV detector at 280 nm and pooled and then analyzed by 12% SDS-PAGE. Fractions with the RIP-PEG conjugate was collected and concentrated and then dialyzed against 50 mM phosphate buffer ( pH 7.0). The RIP-PEG conjugate at 10 mg/ml was filtered through 0.22-mm membrane and stored at 48C until use.
Cell culture Cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (Gibco BRL, Grand Island, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Gibco BRL), 100 mg/ml penicillin and 100 U/ml streptomycin in a 5% CO 2 incubator (Thermo Forma 3110, Waltham, USA).
Measurement of cell growth inhibition by MTT assay
The MTT assay was used to evaluate the cytotoxicity of the RIP or RIP-PEG conjugate in human epidermal carcinoma A431 cells and immortalized human keratinocyte HaCaT cells. The stock solution of MTT [3-(4,5-dimethylthiozol-2-yl)-3,5-dipheryl tetrazolium bromide] (Sigma) was prepared using sterilized phosphate-buffered saline (PBS) of 5 mg/ml. The cells were suspended in DMEM supplemented with 10% fetal calf serum (pH 7.0-7.2), and seeded in 96-well plates (2 Â 10 4 cells/well) and incubated at 378C for 7 h in the incubator with 5% CO 2 . Then, these cells were exposed to the RIP or RIP-PEG conjugate at 33, 3.3, 0.33, or 0.033 mM for 96 h. For A431 cells, 3.3 mM RIP or RIP-PEG conjugate was added followed by 48, 72 and 96 h incubation. Each concentration was tested in quadruplicate. At the end of the treatment, the cells were photographed under phase contrast microscope (TH4-200, Olympus, Tokyo, Japan). The 20 ml (5 mg/ml) of MTT was then added to each well and the plates were incubated at 378C for 4 h. To each well 100 ml of acidified isobutyl alcohol (0.04 M HCl in isopropanol) was added. The OD of each well was read by a microplate spectrophotometer (Model 680, Bio-RAD, Hercules, USA) equipped with 570 nm filter. Cells without the RIP or RIP-PEG conjugate were used as control. The percentage of inhibition was calculated by the following formula, and experiments were repeated three times.
Caspase-3 activity assay The activity of caspase-3 was determined using the caspase-3 activity kit (Beyotime Institute of Biotechnology, Nantong, China). To evaluate the activity of caspase-3, A431 cells were treated with the 3.3 mM RIP or RIP-PEG conjugate, the cell lysates were respectively collected at 0, 12, 24, 36 h after exposure. After incubating the mixture composed of 10 ml of cell lysate, 80 ml of reaction buffer [1% NP-40, 20 mM Tris -HCl ( pH 7.5), 137 mM NAD, and 10% glycerol] and 10 ml of 2 mM caspase-3 substrate (Ac-DEVD-pNA) in 96-well microtiter plates at 378C for 4 h, samples were measured using the microplate spectrophotometer at 405 nm. The caspase activities were measured as fold of enzyme activity in comparison with control. All the experiments were carried out three times.
Hoechst 33258 staining
Apoptotic morphological changes in the nuclear chromatin of A431 cells were detected by Hoechst 33258 staining using the apoptotic nuclear chromatin staining kit (Applygen Technologies Inc., Beijing, China). A431 cells were incubated in DMEM with 10% FBS in 50-ml flask. Twenty-four hours later, cells were treated with the 3.3-mM RIP or RIP-PEG conjugate. Cells incubated in the absence of the RIP or RIP-PEG were used as control. After incubation for 48 h, cells were collected by centrifuging for 5 min at 1000 rpm and washed with PBS and then fixed with 4% paraformaldehyde for 10 min, and incubated with 50 mM Hoechst33258 staining solution for 10 min. After three washes with PBS, the cells were observed by a fluorescence microscope (TH4-200, Olympus).
DNA fragmentation analysis
After exposure to different concentrations of the RIP or RIP-PEG conjugate (0, 3.3 mM) for 48 h, A431 cells (1 Â 10 6 cells) were collected and rinsed with cold PBS. Fragmented DNA was isolated by apoptotic DNA ladder kit (Applygen Technologies Inc.) according to the manufacturer's instructions. The eluate containing DNA pellets were electrophoresed on a 1.0% agarose gel at 45 V for 3 h. The gel was examined and photographed by an ultraviolet gel documentation system (Bio-RAD).
Flow cytometric analysis
Cellular DNA content and cell distribution were quantified by flow cytometry using propidium iodide (PI). After treatment with the RIP or RIP-PEG conjugate (3.3 mM) for 48 h, cells were collected and washed in ice-cold PBS and fixed with 70% ethanol. The fixed cells were harvested by centrifugation at 1000 rpm for 5 min and dissolved in 1 ml PBS containing 50 mg/ml RNase A, 50 mg/ml PI, 0.1% Triton X-100, and 0.1 mM EDTA ( pH 7.4), and incubated at 378C for 30 min. The fluorescence was measured by flow cytometry (ELITE ESP, Coulter, Fullerton, USA).
Immunogenicity analysis BALB/C mice were randomly classified into control, RIP, and RIP-PEG conjugate groups with 10 mice in each group. The mice were injected subcutaneously with the RIP or RIP-PEG conjugate emulsified in Freund's complete adjuvant in four limbs at the dose of 2 mg/kg. Two weeks and 4 weeks after the first injection, two booster injections of the RIP or RIP-PEG conjugate emulsified in Freund's incomplete adjuvant were given to each mouse. Two weeks after the booster injection, blood samples were collected from the capillary vessel in mice's eyes. Separated sera were prepared and stored at 2208C.
Antigen-specific serum IgG levels were measured by ELISA. Briefly, 96-well plates were coated with 100 ml of 3 mg/ml purified antigen (RIP) in 0.1 M carbonatecoating buffer, pH 9.5, and incubated overnight at 48C. After washing, 300 ml of PBS containing 10% FBS, pH 7.4, were added to each well followed by 2 h incubation at 378C. Diluted sera (1:16) were added (100 ml/well) and followed by 2 h incubation at 378C. Wells were then washed in PBS washing buffer, pH 7.4, containing 0.05% Tween-20, and then incubated with peroxidaseconjugated AffiniPure goat anti-mouse IgG (1:40,000) for 1 h at 378C. Then, the plate was washed five times in PBST followed by the addition of 100 ml/well tetramethyl benzidine (Sigma) as a substrate for horseradish peroxidase. The reactions were allowed to develop at 378C for 15 min. Then, 50 ml of 2 M sulfuric acid was added to stop the reaction. The absorbance was measured with the microplate spectrophotometer at 450 nm.
Statistical analysis
All assays were conducted three times. Data are presented as mean + SD. The Duncan test and one-way analysis of variance were used for multiple comparisons (SPSS version 13.0, SPSS, Chicago, USA).
Results
PEGylation of RIP from bitter melon seeds As examined by SDS-PAGE, PAGE, gradient PAGE and TSK 3000 column, pure bitter melon RIP was obtained through extraction and chromatography with SP-Sepharose FF and Superdex 75. RIP is an alkaline glycoprotein consisting of a single polypeptide chain with a molecular mass of 30 kDa and a pI of 9.0. Protein sequencing indicated a homogenous N-terminal with a sequence of N-Asp-Val-Ser-Phe-Arg.
Modified products of RIP with PEG polymer were separated on Superdex 200 molecular sieve column and analyzed by SDS-PAGE. The results showed that modified products were free RIP and RIP-PEG conjugate. The molecular weight of the targeted RIP-PEG conjugate is within 70 -110 kDa by SDS-PAGE in non-reducing conditions, indicating that 2-4 of PEG molecules were conjugated on each RIP molecule (Fig. 1) . The purity and molecular weight of the RIP-PEG conjugate were also analyzed by HPLC (Fig. 2) .
Effects of RIP and RIP-PEG conjugate on the proliferation of A431 and HaCaT cells As Fig. 3 showed, both the RIP and RIP-PEG conjugate exhibited dose-and time-dependent inhibition to the growth of human epidermal carcinoma A431 cells. Under the same concentration, PEGylation of RIP allowed to some extent decrease, approximately 20%, compared with the native RIP in A431 cells [ Fig. 3(A,B) ]. However, cell growth inhibition of the RIP and RIP-PEG conjugate to HaCaT cells demonstrated a significant decrease to A431 cells, indicating that both the RIP and RIP-PEG conjugate displayed stronger inhibition against cancer cells than against normal cells [ Fig. 3(C) ].
Under a phase contrast microscope, untreated A431 cells displayed extended and flat cell shape. After exposure to 33 mM of the RIP or RIP-PEG conjugate for 96 h, A431 cells showed typical apoptotic morphological changes such as blebbing, loss of membrane asymmetry, cell shrinkage, etc. [Fig. 4(A-C) ]. In contrast, the majority of either the treated or untreated HaCaT cells displayed normal morphological performance [ Fig. 4(D-F) ].
Caspase-3 activity
As an execution caspase, caspase-3 plays a pivotal role in apoptotic initiation. As shown in Fig. 5, the 3.3 mM RIP or RIP-PEG conjugate treatment triggered timedependent increase in caspase-3 activity, which was first detected at 12 h, reached peak at 24 h. The activity was maintained until 36 h after treatment.
Nuclear morphological changes
As Fig. 6 showed, under fluorescence microscope, untreated A431 cells displayed extended and flat cell bodies with uniform chromatin across the nuclei, whereas treated cells by RIP or RIP-PEG conjugate showed nuclear morphological changes with apoptotic 
DNA fragmentation
After the A431 cells were exposed to the 3.3-mM RIP or RIP-PEG conjugate for 48 h, typical DNA laddering was observed (Fig. 7) . In contrast, no DNA laddering was observed in untreated A431 cells. Thus, DNA laddering further confirmed that RIP or RIP-PEG conjugate could induce apoptosis in A431 cells.
Detection of apoptotic A431 cells induced by RIP and RIP-PEG conjugate
To further measure the apoptotic induction activity of the RIP and RIP-PEG conjugate, A431 cells were stained with PI, and the sub-G 1 cell population was examined by flow cytometry. After treatment with the 3.3-mM RIP or RIP-PEG conjugate for 48 h, massive cell death was observed as indicated by the emerging of large amount of sub-G 1 population. This treatment also resulted in accumulation of cells in the G 1 phase and reduction of cells in the S phase along with blockage of cell proliferation (Fig. 8) . The G 1 phase arrest eventually led to cell deaths at protracted incubation with the 3.3-mM RIP or RIP-PEG conjugate. Cell cycle analysis indicated that treatment with the RIP or RIP-PEG conjugate decreased the proportion of cells in the S phase and increased the proportion of cells in the G 0 /G 1 and G 2 /M phases of cell cycle. In untreated A431 cells, the mean apoptotic population was 5.0%, which increased to 46.7% and 27.0% after treatment with the 3.3 mM RIP and RIP-PEG conjugate for 48 h, respectively (Fig. 8) .
The number of G 0 /G 1 phases of apoptotic A431 cells increased from 45.0% to 81.1% and 55.7% after 48 h of exposure to the 3.3 mM RIP or RIP-PEG conjugate, the G 2 /M phase increased from 4.6% to 11.8% and 35.3%, whereas the S phase decreased from 50.3% to 7.1% and 9.0%, respectively (Fig. 8) .
Immunogenicity analysis of RIP-PEG conjugate and RIP in vivo The antigenicity of RIP and RIP-PEG conjugate was evaluated by measuring the specific IgG antibody titers of the serum of the BALB/c mice immunized with RIP or RIP-PEG conjugate. As shown in Fig. 9 , the serum obtained from the mice immunized with RIP-PEG conjugate produced IgG antibody titer was lower than the antibody titer produced using RIP.
Discussion
Apoptosis, a programmed process of cell death controlled at the gene level, has been considered a 'final common pathway of cell suicide'. It plays important roles in embryonic development, tissue homeostasis maintenance, and elimination of stray and DNAdamaged cells [19, 20] . Histologically, apoptotic cells are characterized by morphological alterations such as cell shrinkage, nuclear chromatin compaction, pyknosis, nuclear fragmentation, cytoplasmic condensation, and convolution of the nuclear and cell outlines [21] . Our results showed that the RIP or RIP-PEG conjugate induced apoptosis and suppressed A431 cell proliferation in a time-and dose-dependent manner. Under the same concentration, the inhibition rate of RIP-PEG conjugate for A431 is about 60% of RIP. But both the RIP and RIP-PEG conjugate showed little toxic to immortalized human keratinocyte HaCaT cells. Because of the steric effect of surface tethered hydrophilic PEG chains on receptor bindings of cells or protein -protein interactions or PEG molecules may overlay the surface of the RIP, the partial active sites of the RIP were blocked, and the PEGylated proteins exhibited the slight loss of biologic activities in vitro.
Cysteine aspartases (caspases), a protease family, are known to be required for apoptosis induced by various stimuli [22] . Among mammalian caspases, comprising at least 14 known members, caspase-3 is thought to be the main effecter of caspases and has been identified as being activated in response to cytotoxic drugs [22] . Activation of caspase-3 is an important step in the execution phase of apoptosis and its inhibition blocks cell apoptosis [23] . In mammals, caspase-3 has been identified as key executors of apoptosis and is one of the most important caspases activated downstream of apoptotic pathways [24] , which activates caspase-activated DNase, causing apoptotic DNA fragmentation. In order to determine whether RIP and RIP-PEG conjugate could induce apoptosis via caspase pathway, we examined caspase-3 activities and DNA fragmentations. We found that caspase-3 activation persisted in a time-dependent manner when exposed to RIP and RIP-PEG conjugate. The occurrence of DNA laddering in the exposed cells further confirmed the apoptotic-inducing activity of RIP.
Our data demonstrated that RIP and RIP-PEG conjugate have a high capacity of suppressing cell proliferation and triggering apoptosis of human epidermal carcinoma A431 cells in a time-and dose-dependent manner. Therefore, it may have therapeutic potential as an anticancer drug candidate. We also found that RIP and RIP-PEG conjugate can induce accumulation of cells arrested at G 1 phases of the cell cycle and cell apoptosis which may result in multiple mechanisms of action. It appears that the terminal stage apoptotic cells and necrotic cells were predominant 48 h later, which was more significant in the 3.3 mM RIP-treated group. Hence, it suggested that the inhibitory effect of RIP and RIP-PEG conjugate on A431 cells was mediated through the apoptotic pathway.
Immunogenicity of antigen has been the major barrier for in vivo application of protein therapeutic agents. In this study, we used the anti-serum IgG levels to estimate the immunogenicity of antigens in the animals. Results showed that the immunogenicity of the RIP-PEG conjugate was reduced significantly. This result is similar to PEG-methioninase, another PEGylated anti-cancer enzyme [25] . The PEGylated methioninase conjugate Figure 9 The specific IgG antibody titer of mice immunized with RIP or RIP-PEG conjugate The specific IgG antibody titers of the serum of the BALB/c mice immunized with RIP or RIP-PEG conjugate were determined using ELISA as described in 'Materials and Methods'. The specific IgG antibody titers of RIP-PEG conjugate decreased significantly compared with that of RIP (P , 0.05).
also demonstrated an increased pharmacokinetic efficacy by increasing plasma half-life in vivo. Future studies of the RIP-PEG conjugate should involve pharmacokinetic investigations, since long-term retention of RIP depletion in vivo is very important to its future clinical applications.
In conclusion, we isolated and purified the RIP from bitter melon, and chemically modified the protein with PEG. Both the RIP and RIP-PEG conjugate showed a strong anti-tumor activity through apoptotic pathway, with less toxicity to normal cells. Moreover, the reduced antigenicity of the RIP in vivo was also achieved by the PEG modification of RIP. Thus, successful PEG modification of the RIP moved one step forward for its in vivo applications.
